Health Care • Medical/Dental Instruments
$62.48 ▲ +1.06
(+1.73%)
MKT CAP: $3.18B • VOL: 702.4K
52W L $25 52W H $63
ATRC // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $534.5M | $465.3M | $399.2M |
| YoY Revenue Growth % | +14.9% | +16.5% | — |
| Gross Profit | $400.8M | $347.5M | — |
| Gross Margin % | 75.0% | 74.7% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$9.4M | -$40.0M | -$26.7M |
| Operating Margin % | -1.8% | -8.6% | -6.7% |
| Net Income (GAAP) | -$11.4M | -$44.7M | -$30.4M |
| EBITDA (Normalized) | -$2.2M | -$30.8M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $57.3M | $12.2M | $4.5M |
| Capital Expenditures (CapEx) | $9.1M | $11.5M | — |
| Free Cash Flow (FCF) | $48.3M | $745.0K | $4.5M |
| FCF Margin % | 9.0% | 0.2% | 1.1% |
| Return on Invested Capital (ROIC %) | -1.9% | -7.9% | — |
| Cash & Short-Term Equivalents | $167.4M | $122.7M | — |
| Total Debt (Short + Long Term) | $61.9M | $61.9M | — |
| Total Stockholders' Equity | $491.9M | $461.0M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR ATRC.